Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
OnKure Therapeutics, Inc. (OKUR)
USD4.21
-0.01 (-0.24%)
US NASDAQ Healthcare Biotechnology
Address
6707 Winchester Circle 80301
Boulder, CO, US
Boulder, CO, US
CEO
Nicholas A. Saccomano
Website
onkuretherapeutics.com
IPO
2021-04-08
CIK 1637715 ISIN US68277Q1058
Description
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.21
-0.01 (-0.24%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
304.1K
Beta
0.28
Float Shares
8.20M
Free Float %
60.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.45% | -15.25% | -21.16% | +40.66% | +10.06% | +16.90% | +73.85% | -95.83% | -96.96% | -97.74% | -97.74% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
4.21
Low
35.00
+731.4%
Consensus
35.00
+731.4%
Median
35.00
+731.4%
High
35.00
+731.4%
DCF (Unlevered)
4.23
+0.4%
DCF (Levered)
4.33
+2.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
35.00
+731.4%
|
Quality scores
Altman Z-Score
0.50
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-11.4% Q1'26: +6.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +850.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.3% ★ Q1'26: +1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 3 EPS Ana. |
Dec 2029 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 666.7K (-100.0%)
|
500.0K
500.0K – 500.0K
-25.0% YoY
|
666.7K
666.7K – 666.7K
+33.3% YoY
|
1.00M
1.00M – 1.00M
+50.0% YoY
|
—
— – —
-100.0% YoY
|
| EBITDA |
-51.71M
|
-62.12M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-52.37M
|
-62.95M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-52.67M
est: -37.79M (-39.4%)
|
-59.52M
est: -61.43M (+3.1%)
|
-35.48M
-48.64M – -22.33M
+42.2% YoY
|
-28.72M
-31.35M – -26.10M
+19.0% YoY
|
-28.89M
-30.60M – -27.19M
-0.6% YoY
|
-21.36M
-21.36M – -21.36M
+26.1% YoY
|
| SGA |
10.59M
|
14.69M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-3.95
est: -2.83 (-39.4%)
|
-4.40
est: -4.56 (+3.5%)
|
-2.79
-3.60 – -1.65
+38.8% YoY
|
-2.13
-2.32 – -1.93
+23.7% YoY
|
-2.18
-2.26 – -2.01
-2.2% YoY
|
-1.58
-1.58 – -1.58
+27.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
563.00
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
1
-41 vs prev Q
New positions
0
Closed positions
41
Increased
0
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ACORN CAPITAL ADVISORS, LLC | 2.84M +— (+0.0%) | 8.24M +426.0K (+5.5%) | 21.02% +0.000 pp | 2.79% -1.174 pp | USD5.54 -47.7% | 5 qtrs — |
| 2 | ADAR1 CAPITAL MANAGEMENT, LLC | 1.01M +1.0M (+100.0%) | 2.94M +2.9M (+100.0%) | 7.51% +7.507 pp | 0.22% +0.216 pp | USD2.90 +0.0% | 4 qtrs — |
| 3 | PROSIGHT MANAGEMENT, LP | 816.9K +549.0K (+204.9%) | 2.37M +1.6M (+221.5%) | 6.05% +4.064 pp | 0.49% +0.318 pp | USD3.44 -15.7% | 5 qtrs — |
| 4 | SHAY CAPITAL LLC | 780.9K -137.1K (-14.9%) | 2.26M -259.8K (-10.3%) | 5.78% -1.015 pp | 0.23% +0.015 pp | USD2.83 +2.5% | 5 qtrs — |
| 5 | ROSALIND ADVISORS, INC. | 730.5K +730.5K (+100.0%) | 2.12M +2.1M (+100.0%) | 5.41% +5.407 pp | 0.74% +0.745 pp | USD2.90 +0.0% | 1 qtrs NEW |
| 6 | VESTAL POINT CAPITAL, LP | 635.0K +— (+0.0%) | 1.84M +95.3K (+5.5%) | 4.70% +0.000 pp | 0.06% -0.016 pp | USD8.60 -66.3% | 5 qtrs — |
| 7 | VANGUARD GROUP INC | 626.6K -51.6K (-7.6%) | 1.82M -48.0K (-2.6%) | 4.64% -0.382 pp | 0.00% +0.000 pp | USD8.60 -66.3% | 5 qtrs — |
| 8 | HIGHBRIDGE CAPITAL MANAGEMENT LLC | 542.4K -107.9K (-16.6%) | 1.57M -215.3K (-12.0%) | 4.01% -0.798 pp | 0.05% -0.028 pp | USD6.24 -53.5% | 5 qtrs — |
| 9 | NEA MANAGEMENT COMPANY, LLC | 478.5K +— (+0.0%) | 1.39M +71.8K (+5.5%) | 3.54% +0.000 pp | 0.07% -0.002 pp | USD8.60 -66.3% | 5 qtrs — |
| 10 | STEPSTONE GROUP LP | 491.9K +— (+0.0%) | 1.35M +— (+0.0%) | 3.64% +0.000 pp | 0.72% +0.088 pp | USD8.60 -66.3% | 5 qtrs — |
| 11 | CANTOR FITZGERALD, L. P. | 445.1K -46.8K (-9.5%) | 1.29M -61.9K (-4.6%) | 3.29% -0.346 pp | 0.02% +0.006 pp | USD2.99 -3.0% | 5 qtrs — |
| 12 | CARLYLE GROUP INC. | 269.9K +— (+0.0%) | 771.9K +29.7K (+4.0%) | 2.00% +0.000 pp | 0.01% -0.011 pp | USD8.60 -66.3% | 5 qtrs — |
| 13 | RENAISSANCE TECHNOLOGIES LLC | 247.4K +71.6K (+40.7%) | 717.3K +234.0K (+48.4%) | 1.83% +0.530 pp | 0.00% +0.001 pp | USD3.67 -21.0% | 5 qtrs — |
| 14 | CITADEL ADVISORS LLC | 223.1K -793.5K (-78.1%) | 647.1K -2.1M (-76.9%) | 1.65% -5.874 pp | 0.00% 0.000 pp | USD8.48 -65.8% | 5 qtrs — |
| 15 | KOTLER KEVIN | 197.7K +197.7K (+100.0%) | 573.3K +573.3K (+100.0%) | 1.46% +1.463 pp | 0.13% +0.134 pp | USD2.90 +0.0% | 1 qtrs NEW |
| 16 | RANGELEY CAPITAL, LLC | 145.0K -10.5K (-6.7%) | 420.5K -7.1K (-1.7%) | 1.07% -0.078 pp | 0.35% -0.021 pp | USD2.68 +8.2% | 3 qtrs — |
| 17 | AISLING CAPITAL MANAGEMENT LP | 88.6K +— (+0.0%) | 257.0K +13.3K (+5.5%) | 0.66% +0.000 pp | 0.05% +0.000 pp | USD8.60 -66.3% | 5 qtrs — |
| 18 | GEODE CAPITAL MANAGEMENT, LLC | 77.5K -7.4K (-8.7%) | 224.7K -8.8K (-3.8%) | 0.57% -0.055 pp | 0.00% +0.000 pp | USD8.12 -64.3% | 5 qtrs — |
| 19 | SPHERA FUNDS MANAGEMENT LTD. | 60.5K +— (+0.0%) | 175.3K +9.1K (+5.5%) | 0.45% +0.000 pp | 0.03% -0.001 pp | USD8.60 -66.3% | 5 qtrs — |
| 20 | BLACKROCK, INC. | 52.7K -512.2K (-90.7%) | 152.8K -1.4M (-90.2%) | 0.39% -3.791 pp | 0.00% +0.000 pp | USD3.37 -13.9% | 5 qtrs — |
| 21 | GSA CAPITAL PARTNERS LLP | 45.9K -13.3K (-22.4%) | 133.0K -30.0K (-18.4%) | 0.34% -0.098 pp | 0.01% -0.002 pp | USD2.62 +10.7% | 3 qtrs — |
| 22 | ALDEBARAN CAPITAL, LLC | 41.3K -2.7K (-6.2%) | 119.7K -1.3K (-1.0%) | 0.31% -0.020 pp | 0.11% -0.004 pp | USD8.60 -66.3% | 5 qtrs — |
| 23 | BARCLAYS PLC | 27.2K +26.6K (+4,286.8%) | 79.0K +77.3K (+4,525.4%) | 0.20% +0.197 pp | 0.00% +0.000 pp | USD3.03 -4.3% | 5 qtrs — |
| 24 | TWO SIGMA ADVISERS, LP | 26.6K +— (+0.0%) | 77.2K +4.0K (+5.5%) | 0.20% +0.000 pp | 0.00% +0.000 pp | USD6.51 -55.5% | 5 qtrs — |
| 25 | MORGAN STANLEY | 25.0K +7.7K (+45.0%) | 72.4K +25.1K (+52.9%) | 0.18% +0.057 pp | 0.00% +0.000 pp | USD2.86 +1.4% | 5 qtrs — |
| 26 | HSBC HOLDINGS PLC | 20.0K +20.0K (+100.0%) | 57.7K +57.7K (+100.0%) | 0.15% +0.148 pp | 0.00% +0.000 pp | USD2.90 +0.0% | 1 qtrs NEW |
| 27 | NORTHERN TRUST CORP | 19.9K -2.6K (-11.6%) | 57.7K -4.2K (-6.8%) | 0.15% -0.019 pp | 0.00% +0.000 pp | USD7.68 -62.2% | 5 qtrs — |
| 28 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 19.5K +— (+0.0%) | 56.6K +2.9K (+5.5%) | 0.14% +0.000 pp | 0.00% +0.000 pp | USD4.30 -32.6% | 4 qtrs — |
| 29 | JANE STREET GROUP, LLC | 19.4K +19.4K (+100.0%) | 56.3K +56.3K (+100.0%) | 0.14% +0.144 pp | 0.00% +0.000 pp | USD2.90 +0.0% | 1 qtrs NEW |
| 30 | XTX TOPCO LTD | 17.8K +17.8K (+100.0%) | 51.6K +51.6K (+100.0%) | 0.13% +0.132 pp | 0.00% +0.001 pp | USD2.90 +0.0% | 5 qtrs — |
| 31 | TWO SIGMA INVESTMENTS, LP | 11.3K -14.1K (-55.5%) | 32.8K -37.1K (-53.1%) | 0.08% -0.105 pp | 0.00% 0.000 pp | USD4.30 -32.6% | 4 qtrs — |
| 32 | WELLS FARGO & COMPANY/MN | 11.0K +1.5K (+15.8%) | 31.9K +5.8K (+22.1%) | 0.08% +0.011 pp | 0.00% +0.000 pp | USD3.78 -23.3% | 5 qtrs — |
| 33 | CITIGROUP INC | 3.7K +405.0 (+12.2%) | 10.8K +1.7K (+18.3%) | 0.03% +0.003 pp | 0.00% +0.000 pp | USD2.96 -2.0% | 5 qtrs — |
| 34 | UBS GROUP AG | 1.2K +1.0K (+489.3%) | 3.5K +2.9K (+521.3%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD3.75 -22.7% | 5 qtrs — |
| 35 | JPMORGAN CHASE & CO | 545.00 +122.0 (+28.8%) | 1.6K +418.0 (+35.9%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD4.43 -34.5% | 5 qtrs — |
| 36 | FMR LLC | 400.00 +350.0 (+700.0%) | 1.2K +1.0K (+740.6%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD2.88 +0.7% | 2 qtrs — |
| 37 | BNP PARIBAS ARBITRAGE, SNC | 281.00 -83.0 (-22.8%) | 815.00 -186.0 (-18.6%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD6.76 -57.1% | 5 qtrs — |
| 38 | BANK OF AMERICA CORP /DE/ | 141.00 -755.0 (-84.3%) | 409.00 -2.1K (-83.4%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD3.94 -26.4% | 5 qtrs — |
| 39 | TRUST CO OF TOLEDO NA /OH/ | 136.00 +— (+0.0%) | 394.00 +20.0 (+5.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.39 +21.3% | 3 qtrs — |
| 40 | ADVISOR GROUP HOLDINGS, INC. | 109.00 +9.0 (+9.0%) | 316.00 +41.0 (+14.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.43 +19.3% | 5 qtrs — |
| 41 | GROUP ONE TRADING, L.P. | 56.00 +— (+0.0%) | 162.00 +8.0 (+5.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.59 -66.2% | 5 qtrs — |
| 42 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 2.00 +2.0 (+100.0%) | 6.00 +6.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.50 +16.0% | 1 qtrs NEW |
| 43 | MAI CAPITAL MANAGEMENT | — -6.0 (-100.0%) | — -17.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 44 | ROYAL BANK OF CANADA | — -190.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 45 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | — -2.3K (-100.0%) | — -6.2K (-100.0%) | 0.00% -0.017 pp | 0.00% -0.001 pp | USD— | 5 qtrs SOLD |
| 46 | TANG CAPITAL MANAGEMENT LLC | — -116.4K (-100.0%) | — -320.1K (-100.0%) | 0.00% -0.862 pp | 0.00% -0.012 pp | USD— | 5 qtrs SOLD |
| 47 | TOWER RESEARCH CAPITAL LLC (TRC) | — -1.9K (-100.0%) | — -5.3K (-100.0%) | 0.00% -0.014 pp | 0.00% 0.000 pp | USD— | 5 qtrs SOLD |
| 48 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | — -497.0 (-100.0%) | — -1.4K (-100.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 49 | GF FUND MANAGEMENT CO. LTD. | — -271.0 (-100.0%) | — -745.0 (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 38 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.03% | 374.7K | 0.60% |
| 2 | iShares Russell 2000 Value ETF IWN | 0.01% | 963.9K | 0.24% |
| 3 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.00% | 107.0K | 0.30% |
| 4 | Global X - Russell 2000 ETF RSSL | 0.00% | 52.5K | 0.08% |
| 5 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.00% | 11.3K | 0.25% |
| 6 | Avantis U.S. Small Cap Equity ETF AVSC | 0.00% | 99.0K | 0.25% |
| 7 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 1.7K | 0.39% |
| 8 | iShares Russell 2000 ETF IWM | 0.00% | 2.48M | 0.19% |
| 9 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.00% | 16.2K | 0.36% |
| 10 | ProShares - Ultra Russell2000 UWM | 0.00% | 4.4K | 1.07% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
660.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+660,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Saccomano Nicholas A | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 330,000 | 4.07 | 1.34M | 330,000 | D | ↗ |
| 2026-04-01 | Leverone Jason A. | Officer | A-Award | A | Employee Stock Option (right to buy) | 110,000 | 4.07 | 447.7K | 110,000 | D | ↗ |
| 2026-04-01 | Hartley Dylan | Officer | A-Award | A | Employee Stock Option (right to buy) | 110,000 | 4.07 | 447.7K | 110,000 | D | ↗ |
| 2026-04-01 | Agresta Samuel | Officer | A-Award | A | Employee Stock Option (right to buy) | 110,000 | 4.07 | 447.7K | 110,000 | D | ↗ |
| 2026-03-31 | Ratcliffe Liam | Director | A-Award | A | Stock Option (right to buy) | 15,300 | 4.14 | 63.3K | 15,300 | D | ↗ |
| 2026-03-31 | AI Biotechnology LLC | 10% Owner | — | — | Class A Common Stock | 0 | 0.00 | — | 3,998,332 | D | ↗ |
| 2026-03-23 | Saccomano Nicholas A | Director / Officer | S-Sale | D | Class A Common Stock | 86 | 4.16 | 357.46 | 7,333 | D | ↗ |
| 2026-03-23 | Leverone Jason A. | Officer | S-Sale | D | Class A Common Stock | 301 | 4.16 | 1.3K | 16,000 | D | ↗ |
| 2025-12-31 | Mathers Edward T | Director | A-Award | A | Class A Common Stock | 3,911 | 0.00 | — | 15,310 | D | ↗ |
| 2025-12-31 | Manke Isaac | Director | A-Award | A | Class A Common Stock | 5,258 | 0.00 | — | 20,583 | D | ↗ |
| 2025-12-22 | Saccomano Nicholas A | Director / Officer | S-Sale | D | Class A Common Stock | 87 | 2.97 | 258.19 | 7,419 | D | ↗ |
| 2025-12-22 | Leverone Jason A. | Officer | S-Sale | D | Class A Common Stock | 302 | 2.97 | 896.25 | 16,301 | D | ↗ |
| 2025-09-30 | Mathers Edward T | Director | A-Award | A | Class A Common Stock | 4,125 | 0.00 | — | 11,399 | D | ↗ |
| 2025-09-30 | Manke Isaac | Director | A-Award | A | Class A Common Stock | 5,545 | 0.00 | — | 15,325 | D | ↗ |
| 2025-09-22 | Saccomano Nicholas A | Director / Officer | S-Sale | D | Class A Common Stock | 88 | 2.62 | 230.87 | 3,506 | D | ↗ |
| 2025-09-22 | Leverone Jason A. | Officer | S-Sale | D | Class A Common Stock | 303 | 2.62 | 794.92 | 12,603 | D | ↗ |
| 2025-06-30 | Mathers Edward T | Director | A-Award | A | Class A Common Stock | 4,694 | 0.00 | — | 7,274 | D | ↗ |
| 2025-06-30 | Manke Isaac | Director | A-Award | A | Class A Common Stock | 6,311 | 0.00 | — | 9,780 | D | ↗ |
| 2025-06-23 | Saccomano Nicholas A | Director / Officer | S-Sale | D | Class A Common Stock | 88 | 2.38 | 209.81 | 3,594 | D | ↗ |
| 2025-06-23 | Leverone Jason A. | Officer | S-Sale | D | Class A Common Stock | 303 | 2.38 | 722.41 | 12,906 | D | ↗ |
| 2025-05-28 | Phillips Andrew John | Director | A-Award | A | Stock Option (right to buy) | 7,650 | 2.44 | 18.7K | 7,650 | D | ↗ |
| 2025-05-28 | Mathers Edward T | Director | A-Award | A | Stock Option (right to buy) | 7,650 | 2.44 | 18.7K | 7,650 | D | ↗ |
| 2025-05-28 | Manke Isaac | Director | A-Award | A | Stock Option (right to buy) | 7,650 | 2.44 | 18.7K | 7,650 | D | ↗ |
| 2025-05-28 | Jansen Valerie Malyvanh | Director | A-Award | A | Stock Option (right to buy) | 7,650 | 2.44 | 18.7K | 7,650 | D | ↗ |
| 2025-05-28 | GREY MICHAEL G | Director | A-Award | A | Stock Option (right to buy) | 7,650 | 2.44 | 18.7K | 7,650 | D | ↗ |
| 2025-05-28 | Carruthers R Michael | Director | A-Award | A | Stock Option (right to buy) | 7,650 | 2.44 | 18.7K | 7,650 | D | ↗ |
| 2025-05-15 | Cormorant Asset Management, LP | 10% Owner | S-Sale | D | Class A Common Stock | 1,813,439 | 1.85 | 3.36M | 0 | I | ↗ |
| 2025-05-15 | ACORN BIOVENTURES, L.P. | 10% Owner | P-Purchase | A | Common Stock | 270,270 | 1.85 | 500.0K | 1,709,944 | D | ↗ |
| 2025-05-15 | ACORN BIOVENTURES 2, L.P. | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 1,129,730 | D | ↗ |
| 2025-05-12 | Cormorant Asset Management, LP | 10% Owner | S-Sale | D | Class A Common Stock | 24,300 | 1.99 | 48.2K | 1,813,439 | I | ↗ |
| 2025-04-07 | Saccomano Nicholas A | Director / Officer | S-Sale | D | Class A Common Stock | 516 | 2.67 | 1.4K | 3,682 | D | ↗ |
| 2025-04-07 | Leverone Jason A. | Officer | S-Sale | D | Class A Common Stock | 1,844 | 2.67 | 4.9K | 13,209 | D | ↗ |
| 2025-04-04 | Saccomano Nicholas A | Director / Officer | S-Sale | D | Class A Common Stock | 358 | 3.33 | 1.2K | 4,198 | D | ↗ |
| 2025-04-04 | Leverone Jason A. | Officer | S-Sale | D | Class A Common Stock | 1,278 | 3.33 | 4.3K | 15,053 | D | ↗ |
| 2025-03-31 | Mathers Edward T | Director | A-Award | A | Class A Common Stock | 2,580 | 0.00 | — | 2,580 | D | ↗ |
| 2025-03-31 | Manke Isaac | Director | A-Award | A | Class A Common Stock | 3,469 | 0.00 | — | 3,469 | D | ↗ |
| 2025-01-27 | Saccomano Nicholas A | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 130,000 | 5.19 | 674.7K | 130,000 | D | ↗ |
| 2025-01-27 | Leverone Jason A. | Officer | A-Award | A | Employee Stock Option (right to buy) | 65,000 | 5.19 | 337.4K | 65,000 | D | ↗ |
| 2025-01-27 | Hartley Dylan | Officer | A-Award | A | Employee Stock Option (right to buy) | 45,000 | 5.19 | 233.6K | 45,000 | D | ↗ |
| 2025-01-27 | Agresta Samuel | Officer | A-Award | A | Employee Stock Option (right to buy) | 45,000 | 5.19 | 233.6K | 45,000 | D | ↗ |
| 2024-10-07 | Leonard Braden Michael | 10% Owner | J-Other | A | Common Stock | 345,739 | 0.00 | — | 345,739 | I | ↗ |
| 2024-10-04 | Saccomano Nicholas A | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-04 | Phillips Andrew John | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-04 | Mathers Edward T | Director | A-Award | A | Stock Option (right to buy) | 15,300 | 18.20 | 278.5K | 15,300 | D | ↗ |
| 2024-10-04 | Manke Isaac | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-04 | Leverone Jason A. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-04 | Jansen Valerie Malyvanh | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-04 | Hartley Dylan | Officer | A-Award | A | Employee Stock Option (right to buy) | 137,603 | 18.20 | 2.50M | 137,603 | D | ↗ |
| 2024-10-04 | GREY MICHAEL G | Director | A-Award | A | Stock Option (right to buy) | 15,300 | 18.20 | 278.5K | 15,300 | D | ↗ |
| 2024-10-04 | Cormorant Asset Management, LP | 10% Owner | — | — | Class A Common Stock | 0 | 0.00 | — | 1,837,739 | I | ↗ |
| 2024-10-04 | Carruthers R Michael | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-04 | Agresta Samuel | Officer | A-Award | A | Employee Stock Option (right to buy) | 131,396 | 18.20 | 2.39M | 131,396 | D | ↗ |
| 2024-10-04 | ACORN BIOVENTURES, L.P. | 10% Owner | — | — | Class A Common Stock | 0 | 0.00 | — | 1,439,674 | D | ↗ |
Executive team
Top executives
Shares Outstanding
13.67M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nicholas A. Saccomano | President, Chief Executive Officer & Director | 858.0K | — |
| Samuel Agresta | Chief Medical Officer | 640.6K | — |
| Jason A. Leverone | Chief Financial Officer | 591.2K | male |
| Isaac Manke | Senior VP of Business Development & Director | 60.5K | — |
| Roberta Alton | Senior Vice President of Clinical Operations | — | female |
| Rogan Nunn | General Counsel & Secretary | — | male |
| Mark L. Boys | Senior Vice President of Discovery Chemistry | — | — |
| James Blake | Senior Vice President of Computational Drug Discovery | — | — |
| Kevin S. Litwiler | Senior Vice President of DMPK & Clinical Pharmacology | — | — |
| Dylan Hartley | Chief Scientific Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OKUR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
